Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

JAK1 inhibitor

- PMLiVE

AbbVie and C2N take tau antibody into clinic

Treatment being assessed for a progressive neurodegenerative disorder

- PMLiVE

Lucid wins med ed consultancy award at Communiqué

It also sees success with a professional education programme for AbbVie

- PMLiVE

Pharma set for a strong 2015 as drug sales jump

Industry looking to put the recent ‘horror’ patent expiry years behind it

- PMLiVE

NHS England sets up new £190m hep C fund

Will see patients gain access to treatments from Gilead and AbbVie

Gilead Sciences

Humira remains top pharma product, but Sovaldi closes in

AbbVie’s blockbuster may be bumped to second place this year

Infographic: RA market snapshot

An overview of the RA biologic patientOur RA market snapshot will provide you with an introduction to the treatment pathways followed by RA patients treated with biologic agents. Our analyses...

Research Partnership

- PMLiVE

AbbVie remains top of immunology sales

But the threat of biosimilars once again threatens to shake up the leader board

- PMLiVE

Harvoni sales rocket in first quarter

Gilead’s new hepatitis C pill generates stellar revenue

Roche Basel Switzerland

Roche maintains top place in biologic sales

But the looming threat of biosimilars is set to shake up the market

- PMLiVE

Top biotech firms saw sales jump in 2014

But rate of growth slowing from the past five years according to new analysis

- PMLiVE

Humira gets OK for childhood psoriasis in Europe

First biologic drug to be approved in the region for children as young as four

- PMLiVE

AbbVie: New firm, new thinking

UK general manager Matt Regan talks to PME about creating an evolved culture from Abbott

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links